Loading clinical trials...
Loading clinical trials...
Astagraf XL® to Understand the Impact of Immunosuppression on De Novo DSA Development and Chronic Immune Activation in Kidney Transplantation
Conditions
Interventions
Tacrolimus
Tacrolimus immediate release
Locations
30
United States
Site US10006
Birmingham, Alabama, United States
Site US10025
Scottsdale, Arizona, United States
Site US10031
Los Angeles, California, United States
Site US10005
Sacramento, California, United States
Site US10016
San Francisco, California, United States
Site US10024
Aurora, Colorado, United States
Start Date
September 9, 2016
Primary Completion Date
June 14, 2019
Completion Date
June 14, 2019
Last Updated
December 18, 2024
NCT04870437
NCT07415421
NCT06958796
NCT07294547
NCT07224763
NCT06972069
Lead Sponsor
Astellas Pharma Global Development, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions